Sundrug Co. Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, was ¥42.41 per share, a gain of 17.6% from ¥36.05 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥5.13 billion, an increase of 12.8% from ¥4.54 billion in the year-earlier period.
The normalized profit margin climbed to 4.2% from 4.0% in the year-earlier period.
Total revenue increased 6.2% year over year to ¥120.70 billion from ¥113.66 billion, and total operating expenses climbed 5.7% from the prior-year period to ¥112.68 billion from ¥106.56 billion.
Reported net income rose 16.8% on an annual basis to ¥5.09 billion, or ¥42.13 per share, from ¥4.36 billion, or ¥34.59 per share.
As of Feb. 13, US$1 was equivalent to ¥118.68.
